Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-SLE upadacitinib in moderately to severely active SLE (Japan)
jRCT2061230060Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in systemic lupus erythematosus (SLE) (10 arms), sponsored by AbbVie Inc. Primary endpoint: BICLA response at Week 52. Started Oct 2023; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2061230060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230060.